Send to

Choose Destination
Am J Clin Oncol. 1988 Oct;11(5):550-2.

Phase II trial of high-dose cytosine arabinoside and cisplatin in recurrent squamous carcinoma of the head and neck. A Piedmont Oncology Association Study.

Author information

Oncology Research Center, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27103.


Fifteen patients with recurrent squamous carcinoma of the head and neck received high-dose cytosine arabinoside (ara-C) (3 g/m2) and cisplatin (100 mg/m2) every 3 weeks in an attempt to explore the dose-dependent synergy between these two agents. A partial response was attained in one patient; there were no complete responses. The major toxicity was myelosuppression. With the current schedule, high-dose ara-C failed to improve the response rate achieved with cisplatin alone.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center